[HTML][HTML] Engineering interferons and interleukins for cancer immunotherapy

PG Holder, SA Lim, CS Huang, P Sharma… - Advanced drug delivery …, 2022 - Elsevier
Cytokines are a class of potent immunoregulatory proteins that are secreted in response to
various stimuli and act locally to regulate many aspects of human physiology and disease …

Antibody targeted drugs as cancer therapeutics

D Schrama, RA Reisfeld, JC Becker - Nature reviews Drug discovery, 2006 - nature.com
Abstract Treatment of cancer is a double-edged sword: it should be as aggressive as
possible to completely destroy the tumour, but it is precisely this aggressiveness which often …

Tumor regression by targeted gene delivery to the neovasculature

JD Hood, M Bednarski, R Frausto, S Guccione… - Science, 2002 - science.org
Efforts to influence the biology of blood vessels by gene delivery have been hampered by a
lack of targeting vectors specific for endothelial cells in diseased tissues. Here we show that …

Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis

S Weis, J Cui, L Barnes, D Cheresh - The Journal of cell biology, 2004 - rupress.org
VEGF is unique among angiogenic growth factors because it disrupts endothelial barrier
function. Therefore, we considered whether this property of VEGF might contribute to tumor …

High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer

G Spizzo, G Gastl, P Obrist, P Went, S Dirnhofer… - Breast cancer research …, 2004 - Springer
Previous studies in small series of patients with invasive breast cancer suggested a
prognostic value of Ep-CAM overexpression in primary tumor tissue. To corroborate these …

Immunocytokines: a novel class of potent armed antibodies

N Pasche, D Neri - Drug discovery today, 2012 - Elsevier
Several cytokines have been investigated in clinical trials, based on their potent therapeutic
activity observed in animal models of cancer and other diseases. However, substantial …

Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy

C Hutmacher, D Neri - Advanced drug delivery reviews, 2019 - Elsevier
Cytokines have long been used for therapeutic applications in cancer patients. Substantial
side effects and unfavorable pharmacokinetics limit their application and may prevent dose …

Engineering antibodies for therapy

LG Presta - Current pharmaceutical biotechnology, 2002 - ingentaconnect.com
With eleven therapeutic antibodies approved worldwide and many more in clinical trials,
research on antibody engineering has continued to escalate and expand. This review …

Antibody–cytokine fusion proteins for the therapy of cancer

ML Penichet, SL Morrison - Journal of immunological methods, 2001 - Elsevier
Advances in genetic engineering and expression systems have led to rapid progress in the
development of antibodies fused to other proteins. These 'antibody fusion proteins' have …

Facts and hopes on chimeric cytokine agents for cancer immunotherapy

Z Ren, X Zhang, YX Fu - Clinical Cancer Research, 2024 - AACR
Cytokines are key mediators of immune responses that can modulate the antitumor activity
of immune cells. Cytokines have been explored as a promising cancer immunotherapy …